Renal denervation for resistant hypertension: a glimpse of hope on the horizon?

Davide Bolignano
CNR – Institute of Clinical Physiology, Reggio Calabria, Italy

ABSTRACT

Renal denervation by a minimally-invasive catheter-based procedure has been extensively studied over the last decade as a powerful tool for treating resistant hypertension, a high-risk condition the clinical management of which remains a major challenge. Initial promising results from uncontrolled pilot studies set the stage for a plethora of larger randomized, sham-controlled trials which, however, had unexpectedly negative findings. Despite this transient setback, positive although weak results from the latest Symplicity Spyral studies and a series of new procedural approaches beyond radiofrequency have rekindled enthusiasm for this procedure. New studies are warranted to fully elucidate, once and for all, the limits and potential of and indications for renal denervation in the treatment of resistant hypertension.

Keywords: renal denervation, resistant hypertension, nerve ablation.

INTRODUCTION

Hypertension remains a major public health problem and one of the most relevant causes of mortality, morbidity and hospitalizations worldwide. In the general populations, the overall prevalence of this condition peaked at 26% in 2000 and it is forecast that more than 1.56 billion patients will be hypertensive by 2025. Roughly 3 to 6% of the whole hypertensive population is considered as “resistant”. Individuals with resistant hypertension, by definition, show an office blood pressure ≥140/90 mmHg despite taking three different classes of antihypertensives (including a diuretic) at maximally tolerated doses or using ≥4 medications irrespective of blood pressure. Resistant hypertension ranks among the most important prognostic risk factors for adverse cardiovascular and renal outcomes. Unfortunately, various dietary, lifestyle or behavioral programs, alone or in addition to stepped therapeutic algorithms, have failed to significantly improve this condition. The search for effective treatments to properly manage resistant hypertension has been acknowledged by the scientific community as a true research priority. In recent years, improved understanding of the role of the sympathetic nervous system and the enormous advancement in health technology have laid the groundwork for several minimally invasive, device-based approaches targeting nervous reflexes that might contribute to an unstable blood pressure control. Among these, renal denervation remains the procedure that has accumulated the most relevant amount of pre-clinical and randomized experience, with over 4000 indexed publications in scientific literature and a wealth of promising, ongoing studies, the results of which are expected to be available within the next few years.


**A RATIONALE FOR RENAL DENERVATION IN RESISTANT HYPERTENSION**

The pathophysiological rationale for renal denervation as a measure for improving blood pressure control relies on the sophisticated bidirectional interaction between the kidney and the sympathetic nervous system. Efferent nervous fibers, the stimulation of which elicits renal vasoconstriction, renin release, retention of water and sodium and blood flow reduction, originate in the brain and terminate in the juxtaglomerular apparatus in the renal cortex after traveling through the spinal cord. On the contrary, afferent fibers arise in the renal pelvis, conveying sympatho-excitatory stimuli to the autonomic regulatory nucleus tractus solitarius in the midbrain. Sympathetic over-reactivity of the renal nervous autonomic plexus plays a key role in the pathophysiology of arterial hypertension, a concept that was already known in the pre-pharmacological era of hypertension management in which the most severe forms were clumsily treated by extensive splanchnicectomy. However, although effective, this unselective, highly destructive surgical approach was unsuitable to be routinely performed, taking into consideration the high peri-operative risk and the several major neurological sequelae that impacted patients’ conditions more significantly than resistant hypertension itself.

In recent years, the smart idea to destruct renal nerves in a minimally invasive way, by means of energy delivered from the lumen of the arterial vascular branches, has injected fresh excitement into the possibility of successfully challenging resistant hypertension using a non-pharmacological approach.

As a result, myriad highly specialized, catheter-based devices have been conceived, leading to a wealth of pre-clinical and clinical experience with contradictory findings that, unfortunately, still prevents the drawing of any final conclusions on the potential use of this procedure in routine practice.

**RENAL DENERVATION BY RADIOFREQUENCY: A “MATTER OF SIMPLICITY”**

Energy delivered by radiofrequency was the first and is the most studied technique to obtain renal nerve ablation and the Symplicity System (Medtronic, US) is the pioneering, catheter-based device which has led the majority of scientific studies conducted so far on renal denervation.

The first generation of this device consisted of a radiofrequency, generator-coupled arched catheter with a max 8W energy delivery to target tissue temperature of 40-75°C. A second spiral version (Symplicity Spyral) was subsequently conceived to overcome the problem of concentrating focal energy into a single artery segment. Other radiofrequency catheters exist, including the OneShot (Medtronic, US; formerly Covidien), the Vessix System (Boston Scientific, US), the EnligHTN (Abbott, US; formerly St. Jude), the PRDS-001 System (Otsuka, Japan), the SyMapCath (Terumo Corporation, Japan), the Synaptic device (Synaptic Medical Limited, China) the Golden Leaf catheter (Shanghai Golden Leaf MedTec Co., China), the saline-irrigated, radiofrequency catheter Thermacool (Biosense-Webster, California, US) and the Iberis System (Terumo Corporation, Japan). Findings on these devices has rapidly accumulated but remains mostly limited to small proof-of-principle, uncontrolled studies.

The SYMPLICITY HTN-1, a large pilot, uncontrolled prospective study, was the first trial demonstrating the Symplicity radiofrequency catheter’s capacity to reduce blood pressure by renal denervation in individuals with resistant hypertension and to maintain this benefit long-term. The SYMPLICITY HTN-2, a multicenter, prospective, open-label, controlled trial, followed soon after. This study randomized 106 resistant hypertensive patients to renal denervation or standard therapy, demonstrating, after 6 months, a reduction in office systolic/diastolic blood pressure in the renal denervation group by 32/12 mmHg (p<0.0001) with no changes in the control group and a between-group difference of 33/11 mmHg (p<0.0001).

The following SYMPLICITY HTN-3 was the first multicenter, randomized, pivotal trial employing a controlled group receiving a sham-procedure. The study recruited 535 participants with resistant hypertension worldwide. Despite high hopes, the study failed to prove the superiority of renal denervation over sham to improve office blood pressure. Unexpectedly, the mean systolic blood pressure decreased at 6 months in both the experimental and control group (-14.13±23.93 and -11.74±25.94 mmHg, respectively; p=0.001 for both comparisons of the change from baseline) with a non-significant between-group difference (p=0.26), an observation confirmed also when looking at the pattern of 24h ambulatory systolic blood pressure. Two other independent randomized studies (14,
15) implementing a sham-control arm echoed such negative findings. Failure of the SYMPPLICITY HTN-3 also led to premature stopping of another sponsored randomized, (non-sham) controlled trial, the SYMPPLICITY HTN-JAPAN16, which results were eventually inconclusive due to underpowering.

Despite this setback apparently crushing spirits and dreams, results from two recent multicenter trials specifically designed to overcome potential limits of the SYMPPLICITY HTN-3 have sparked new enthusiasm about the potential of this procedure.

The SPYRAL HTN-OFF and ON MED trials (17, 18) were two randomized, sham-controlled, proof-of-principle studies implementing the last-generation Symplicity Spyral in the absence (SPYRAL HTN-OFF MED) and presence (SPYRAL HTN-ON MED) of background antihypertensive therapy. In a 3-month analysis of the SPYRAL HTN-OFF MED17, the renal denervation group (n=38) experienced a statistically significant decrease in blood pressure compared with the sham-controlled group (n=42) although change differences were as little as 5 and 4.4 mmHg for 24-h systolic and diastolic ambulatory measurement and 7.7 and 4.9 mmHg for office blood pressure, respectively. The first recently published 6-month interim report of the SPYRAL HTN-ON MED showed similar, clinically limited, benefits18 with systolic and diastolic drop differences between the renal denervation and the sham-control group of 7.4 and 4.1 mmHg for 24h-ABPM and 6.8 and 3.5 mmHg for office blood pressure measurements, respectively.

Three more randomized, open-label, controlled trials adopting the first generation Symplicity catheter deserve mentioning. The PRAGUE-15 trial19 adopting the first generation Symplicity catheter showed similar, clinically limited, benefits18 with systolic and diastolic drop differences between the renal denervation and the sham-control group of 7.4 and 4.1 mmHg for 24h-ABPM and 6.8 and 3.5 mmHg for office blood pressure measurements, respectively.

Finally, the DENERHTN21 compared the efficacy of renal denervation on daytime ambulatory blood pressure control in addition to a structured, stepped-care antihypertensive treatment versus the same treatment alone. Interestingly, this study was apparently the only one reporting convincing results in favor of renal denervation with a mean change in systolic ABPM at 6 months of -15.8 mmHg (95% CI -19.7 to -11.9) versus -9.9 mmHg (95% CI -13.6 to -6.2) in the control group, with a significant baseline-adjusted, between-group difference of -5.9 mmHg (95% CI -11.3 to -0.5; p=0.03). An overview of the most important randomized controlled trials of renal denervation is provided in Table 1.

### Table 1

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Design</th>
<th>Population characteristics</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symplicity HTN-21</td>
<td>Multicenter, randomized, open-label</td>
<td>Individuals with uncontrolled hypertension aged 18-85, systolic BP≥160 (≥150 in diabetes) and ≥3 anti-hypertensive drugs</td>
<td>Renal denervation (n=53) by the Symplicity radiofrequency catheter plus standard treatment</td>
<td>Standard treatment alone (n=54)</td>
<td>Blood pressure in the renal denervation group reduced by 33/11 mm Hg (SD 23/11, baseline of 178/96 mm Hg, p&lt;0.0001) but did not differ from baseline in the control group. Between-group differences in blood pressure at 6 months were 33/11 mm Hg (p&lt;0.0001).</td>
</tr>
<tr>
<td>Symplicity HTN-3</td>
<td>Multicenter, randomized, patients and outcome assessors-blinded</td>
<td>Individuals with uncontrolled hypertension aged 18-80, systolic BP≥160 and ≥3 anti-hypertensive drugs including diuretic</td>
<td>Renal denervation (n=364) by the Symplicity radiofrequency catheter plus standard treatment</td>
<td>Sham procedure plus standard treatment (n=171)</td>
<td>Mean (+/-SD) change in systolic blood pressure at 6 months was -14.13+/ -23.93 in the denervation group vs. -11.74+/ -25.94 mmHg in the sham-procedure group (P=0.01 for both comparisons of the change from baseline; P=0.26 between-group difference).</td>
</tr>
<tr>
<td>Symplicity-FLEX</td>
<td>Single-center, randomized, single-blinded</td>
<td>Individuals with uncontrolled hypertension aged 18-75 and ≥3 anti-hypertensive drugs including diuretic</td>
<td>Renal denervation (n=35) by the Symplicity radiofrequency catheter plus drug treatment</td>
<td>Sham procedure (n=36) plus drug treatment</td>
<td>Mean change in 24h systolic ABPM in the intention to treat cohort at 6 months was -7.0 mm Hg (95% CI -10.8 to -3.2) for patients undergoing denervation and -3.5 mm Hg (95% CI -6.7 to -0.2) in the sham group (P=0.15).</td>
</tr>
<tr>
<td>Study ID</td>
<td>Design</td>
<td>Population characteristics</td>
<td>Intervention</td>
<td>Comparator</td>
<td>Results</td>
</tr>
<tr>
<td>----------</td>
<td>--------</td>
<td>----------------------------</td>
<td>--------------</td>
<td>------------</td>
<td>---------</td>
</tr>
<tr>
<td>RESET15</td>
<td>Single-center, randomized, single-blinded</td>
<td>Individuals with uncontrolled hypertension and daytime systolic ABPM≥145 mmHg following 1 month of stable medication</td>
<td>Renal denervation (n=36) by the Symplicity radiofrequency catheter</td>
<td>Sham procedure (n=33)</td>
<td>Similar reductions in daytime systolic ABPM compared with baseline at 3 months [-6.2 +/- 18.8 mmHg (RDN) vs. -6.0 +/- 13.5 mmHg (SHAM)] and at 6 months [-6.1 +/- 18.9 mmHg (RDN) vs. -4.3 +/- 15.1 mmHg (SHAM)].</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Renal denervation (n=22) by the Symplicity radiofrequency catheter plus standard treatment</td>
<td>Standard treatment alone (n=19)</td>
<td>– 6-month office SBP change was -16.6+/−18.5 mmHg after RDN (P&lt;0.001) and -7.9+/−21.0 mmHg in controls (P=0.117); the difference between the 6-month change in RDN and control was -8.64 (95% CI: -21.12 to 3.84, P=0.169).</td>
</tr>
<tr>
<td>Symplicity HTN-Japan16</td>
<td>Multicenter, randomized, open-label</td>
<td>Individuals with uncontrolled hypertension aged 20-79, BP≥160 and ≥3 anti-hypertensive drugs including diuretic</td>
<td>Renal denervation (n=38) by the Symplicity radiofrequency catheter</td>
<td>Sham procedure (n=42)</td>
<td>Change in blood pressure was significantly greater at 6 months in the renal denervation group than the sham-control group for office systolic blood pressure (difference -7.7 mmHg; p=0.0205), 24h systolic ABPM (difference -5.0 mmHg; p=0.0051), office diastolic blood pressure (difference -4.9 mmHg; p=0.0478), and 24h diastolic ABPM (difference -4.4 mmHg; p=0.0292)</td>
</tr>
<tr>
<td>SYPRAL HTN-OFF MED17</td>
<td>Multicenter, randomized, patients and outcome assessors-blinded</td>
<td>Individuals with mild uncontrolled hypertension aged 20-80, office systolic BP=150-180 and diastolic≥90 and 24h-systolic ABPM=140-170</td>
<td>Renal denervation (n=38) by the Symplicity Sypral radiofrequency catheter</td>
<td>Sham procedure (n=42)</td>
<td>Change in blood pressure was significantly greater at 6 months in the renal denervation group than the sham-control group for office systolic blood pressure (difference -6.8 mmHg; p=0.0205), 24h systolic ABPM (difference -7.4 mmHg; p=0.0051), office diastolic blood pressure (difference -3.5 mmHg; p=0.0478), and 24h diastolic ABPM (difference -4.1 mmHg; p=0.0292)</td>
</tr>
<tr>
<td>SYPRAL HTN-ON MED (18)</td>
<td>Multicenter, randomized, patients and outcome assessors-blinded</td>
<td>Individuals with mild uncontrolled hypertension aged 20-80, office systolic BP=150-180 and diastolic≥90 and 24h-systolic ABPM=140-170</td>
<td>Renal denervation (n=38) by the Symplicity radiofrequency catheter</td>
<td>Sham procedure (n=42)</td>
<td>– Decrease of 8.6 [95% CI -11.8, -5.3] mmHg; p&lt;0.001 in renal denervation versus -8.1 [95% CI -12.7, -3.4] mmHg; p&lt;0.001 in control group</td>
</tr>
<tr>
<td>PRAGUE-15 (19)</td>
<td>Multicenter, randomized, open-label</td>
<td>Individuals with uncontrolled hypertension aged 20-79, systolic BP=140 and ≥3 anti-hypertensive drugs including diuretic</td>
<td>Renal denervation (n=52) by the Symplicity radiofrequency catheter</td>
<td>Intensified treatment including spironolactone (n=54)</td>
<td>– Decrease of -12.4 [95% CI: -17.0, -7.8] mmHg; p&lt;0.001 in renal denervation versus -14.3 [95% CI: -19.7, -8.9] mmHg; p&lt;0.001 in control group</td>
</tr>
<tr>
<td>OSLO RDN (20)</td>
<td>Single-center, randomized, open-label</td>
<td>Individuals with uncontrolled hypertension aged 18-80, systolic BP&gt;140 and ≥3 anti-hypertensive drugs including diuretic</td>
<td>Renal denervation (n=9) by the Symplicity radiofrequency catheter</td>
<td>Adjusted drug treatment (n=10)</td>
<td>– No significant differences between groups</td>
</tr>
<tr>
<td>DENERHTN (21)</td>
<td>Multicenter, randomized, open-label</td>
<td>Individuals with uncontrolled hypertension aged 18-75, BP≥140/90 and ≥3 anti-hypertensive drugs including diuretic</td>
<td>Renal denervation (n=53) by the Symplicity radiofrequency catheter plus a standardized stepped-care antihypertensive treatment</td>
<td>Standardized stepped-care antihypertensive treatment alone (n=53)</td>
<td>Systolic and diastolic BP changed from 160±14/88±13 to 132±10/77±8 mmHg at 6 months (p=0.0005 and p=0.02 respectively) in the control group with no significant change in the active group. Study was prematurely stopped for futility</td>
</tr>
</tbody>
</table>

**RENAL DENERVATION BEYOND RADIOFREQUENCY: ALTERNATIVE METHODS**

Alternative techniques to radiofrequency have been studied for improving renal nerve ablation success and minimize safety risks. The Paradise system (ReCor Medical, US), the TIVUS (Cardiosonic, Israel), the Kona (Kona Medical, US) and the Sound 360 system (Sound Interventions, US) are device-based catheters designed to ablate renal nerves via ultrasound-derived energy generated by a piezoelectric micro-transducer usually placed inside a low-pressure balloon. Efficacy and safety of these devices is object of several ongoing investigations (Table 2).
The Peregrine catheter (Ablative Solutions, US) is coupled with a triple micro-needle system to inject ethanol into the perivascular space. Alcohol is endowed with strong neurolytic effects, leading to fast nerve disruption. Efficacy and safety of this approach is presently being tested by two global, randomized, double-blind, multicenter, sham-controlled trials.

Alternative to ethanol, other neurotoxic agents such as vincristine and the pro-apoptotic neurotrophic agent NW2013 have shown promising findings in small uncontrolled studies.

Further, innovative procedures to achieve renal nerve ablation include vascular brachytherapy with renal sympathetic nerve destruction via β-radiation exposure and cryotherapy.

This latter procedure was successfully conducted in two case series of individuals who were refractory to standard renal denervation by radiofrequency, through a standard electrophysiology cardiac cryoablation catheter targeting a tissue temperature of −75 °C for 4 mins in each renal artery. Positive results with no major damages to kidney and vasculature have laid the groundwork for a larger, non-randomized, controlled study that is currently ongoing.

**DISCUSSION**

Failure of the SYMPLICITY HTN-3 and the other sham-controlled RCTs have brought renal denervation to a screeching halt, which was duly justified by negative findings from pooled efficacy meta-analyses. Nevertheless, recent bittersweet results in clinical benefits from the SPYRAL HTN-OFF/ON MED studies and the large bunch of ongoing studies at the horizon are suggesting that the momentum for renal denervation may continue.

Some key issues which emerged from the SYMPLICITY HTN-3 and the other large sham-controlled trials were not or only marginally addressed by the following SPYRAL evidence. Overcoming these limitations represents a plausible basis for intelligent and unbiased investigations designed to clarify the true usefulness of this procedure in the real world.

One main problem, for instance, is the importance of the study population selection. As a successful blood pressure decrease is usually manifested one month after the procedure, early prediction of responding individuals becomes rather challenging. Renal nerve ablation by radiofrequency or ultrasound energy is mediated by inflammatory or degenerative processes.

<table>
<thead>
<tr>
<th>Study ID</th>
<th>NCT</th>
<th>Country</th>
<th>n.</th>
<th>Device (manufacturer)</th>
<th>RDN Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>SYNAPTIC</td>
<td>NCT03511313</td>
<td>China</td>
<td>264</td>
<td>Synaptic device (Synaptic Medical Limited, China)</td>
<td>Radiofrequency</td>
</tr>
<tr>
<td>Golden Leaf</td>
<td>NCT03261375</td>
<td>China</td>
<td>110</td>
<td>Golden leaf catheter (Golden Leaf MedTec Co., China)</td>
<td>Radiofrequency</td>
</tr>
<tr>
<td>REDUCE HTN:REINFORCE</td>
<td>NCT02392351</td>
<td>US</td>
<td>51</td>
<td>Vessix system (Boston Scientific, Massachussets, US)</td>
<td>Radiofrequency</td>
</tr>
<tr>
<td>IBERIS-HTN</td>
<td>NCT02901704</td>
<td>China</td>
<td>216</td>
<td>Iberis System (Terumo Corp. Japan)</td>
<td>Radiofrequency</td>
</tr>
<tr>
<td>SMART</td>
<td>NCT02761811</td>
<td>China</td>
<td>212</td>
<td>SyMapCath (Terumo Corporation, Japan)</td>
<td>Radiofrequency</td>
</tr>
<tr>
<td>RADIANCE HTN</td>
<td>NCT02649426</td>
<td>US, EU</td>
<td>146</td>
<td>Paradise System (ReCor Medical, California, US)</td>
<td>Ultrasounds</td>
</tr>
<tr>
<td>REQUIRE</td>
<td>NCT02918305</td>
<td>JAP</td>
<td>140</td>
<td>PRDS-001 System (Tosuka, Japan)</td>
<td>Ultrasounds</td>
</tr>
<tr>
<td>RADIANCE II</td>
<td>NCT03614260</td>
<td>US, EU</td>
<td>225</td>
<td>Paradise System (ReCor Medical, California, US)</td>
<td>Ultrasounds</td>
</tr>
<tr>
<td>TARGET BP OFF-MED</td>
<td>NCT03503773</td>
<td>Global</td>
<td>400</td>
<td>Peregrine catheter (Ablative Solutions, Michigan, US)</td>
<td>Ethanol</td>
</tr>
<tr>
<td>TARGET BP I</td>
<td>NCT02910414</td>
<td>Global</td>
<td>100</td>
<td>Peregrine catheter (Ablative Solutions, Michigan, US)</td>
<td>Ethanol</td>
</tr>
</tbody>
</table>
that require some days before leading to a concrete functional damage. This paradigm justifies the search for alternative strategies to speed up or make more efficient the ablation process. As briefly alluded to, various innovative approaches (e.g. brachytherapy, cryotherapy or ethanol injection) for achieving renal nerve ablation are currently the object of multiple investigations.

At present, no concrete, reproducible surrogates of successful denervation exist. Yet, various observations indicate that “one size cannot fit all”, suggesting that future trials should target selected sub-groups of patients rather than the whole resistant hypertensive population. For example, specific analyses of the Global SYMPLICITY Registry, a prospective, multicenter international database collecting information from over 3000 patients who underwent renal denervation, advised excluding persons with large pulse pressure or isolated systolic hypertension as less likely to benefit from this procedure, probably due to pervasive arterial stiffness. Another stratified analysis by racial origin in the SYMPLICITY HTN-3 trial pointed out Caucasian patients in the intervention group as being more prone to experience improvements in systolic BP. Conversely, although initially hypothesized, no impact of BMI on successful renal ablation has been clearly established.

Another important lesson from the SYMPLICITY HTN-3 was the high frequency of medication changes. Roughly 40% of subjects underwent known modifications in their therapeutic regimen during the trial and further data published during and after the study suggested an additional high rate of drug non-adherence that would not otherwise have been known to the investigators. Although the design of subsequent trials of renal denervation began to incorporate serum and urine medication adherence testing, therapeutic compliance remains a significant factor in studies which evaluate this procedure.

The fact that the renal nerves have a specific anatomy in the renal arteries is another key problem. In fact, the distance to the lumen increases as renal nerves track back in the direction of the vessel origin. Therefore, performing the procedure in the lumen of more distal renal vessels may improve success, but may significantly increase the risk of damaging the ureter or the renal veins. Inadequate renal denervation may also depend on the operator’s skills and practice and on inter-operator variability. And, very disappointingly, the majority of specialists performing renal denervation in the SYMPLICITY HTN-3 study were relatively unfamiliar with this technique and performed no more than two procedures during the trial.

CONCLUSIONS

In the wasteland of clinical research into improving blood pressure control and key outcomes in individuals with resistant hypertension, renal denervation remains a very promising technique that, however, deserves additional research efforts to fully elucidate its limits, potential and suitability.

Lessons from past mistakes underline the need to identify early markers of procedural response, defining subpopulations that are more likely to be responsive and optimizing ablation success, perhaps by innovative and more efficacious techniques that are an alternative to radiofrequency. Upcoming research is warranted in the near future, intended to revolutionize the intricate clinical management of such a complex disease condition.

Disclosure of potential conflicts of interest: none declared.

References


Davide Bolignano